OTCM
CARM
Market cap20kUSD
Oct 08, Last price
0.00USD
1D
0.00%
1Q
-90.91%
Jan 2017
-100.00%
IPO
-100.00%
Name
Carisma Therapeutics Inc
Chart & performance
P/E
—
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
55.59%
Rev. gr., 5y
148.16%
Revenues
20m
+31.59%
Net income
-60m
L-30.39%
CFO
-60m
L-26.19%
Dividend
Mar 08, 20230.361 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Key people
Thomas R. Cannell
President, Chief Executive Officer, Director · since 2018
Monica Forbes
Chief Financial Officer and Principal Financial Officer · since 2019
Glen C. MacDonald
Chief Scientific Officer · since 2016
Kirstin Anderson
Principal Accounting Officer, Corporate Controller · since 2019
Gregory P. Adams
Chief Development Officer · since 2016
Independent Director · since 2020
Jay S. Duker
Independent Director · since 2015
Independent Director · since 2014
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
215 1st Street
Suite 400
Cambridge, MA 02142
US
Suite 400
Cambridge, MA 02142
US
Previous name
Eleven Biotherapeutics, Inc.
Previous name
Denovo Therapeutics, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||